Across TCGA pan-cancer cohorts, BLM mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BLM data layer compared with 30 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BLM mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated BLM expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and HNSC are the cancer types where BLM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	III,IV	0.991	0.298	.004	19	view →
CCRCC	DFS	Quartile	All	1.000	0.702	.026	8	view →
HNSC	DFS	Median	IV	0.440	0.773	.033	5	view →
UCEC	DFS	Tertile	III,IV	1.000	0.409	.040	4	view →
LSCC	OS	Quartile	All	0.945	0.730	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: BLM tumor-vs-normal RNA expression · all BLM data types